1. Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study.
- Author
-
Cheol Min Shin, Nayoung Kim, Yong Sung Kim, Ryoung Hee Nam, Ji Hyun Park, Dong Ho Lee, Yeong-Jae Seok, Yeon-Ran Kim, Joo-Hyon Kim, Jung Min Kim, Joo Sung Kim, and Hyun Chae Jung
- Subjects
- *
PROTON pump inhibitors , *CLOSTRIDIUM , *SMALL intestinal bacterial overgrowth , *GASTROESOPHAGEAL reflux , *LANSOPRAZOLE , *THERAPEUTICS , *DISEASES - Abstract
Background/Aims: To evaluate changes in gut microbiota composition following long-term proton pump inhibitor (PPI) treatment. Methods: Twenty-four-week-old F344 rats were fed diets with (n=6) or without (n=5) lansoprazole for 50 weeks. Profiles of luminal microbiota in the terminal ileum were then analyzed. Pyrosequencing of the 16S rRNA gene was performed using an FLX genome sequencer (454 Life Sciences/Roche). Results: Rats treated with lansoprazole showed significantly reduced body weights compared to controls (lansoprazole-treated rats and controls, 322.3±15.3 g vs 403.2±5.2 g, respectively, p<0.001). However, stool frequencies and consistencies did not differ between the two groups. The composition of the gut microbiota in lansoprazole- treated rats was quite different from that of the controls. In the controls, the microbiota profiles obtained from the terminal ileum showed a predominance of Proteobacteria (93.9%) due to the abundance of Escherichia and Pasteurella genera. Conversely, lansoprazole-treated rats showed an elevated population of Firmicutes (66.9%), which was attributed to an increased ratio of Clostridium g4 to Lactobacillus genera. Conclusions: This preliminary study suggests that long-term administration of PPI may cause weight loss and changes to the microbiota in the terminal ileum. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF